Potential Protective Effect of Dl-3-n-Butylphthalide on Chronic Cerebral Ischemia Brain Injury

2021 ◽  
Vol 21 ◽  
Author(s):  
Fangfang Zhao ◽  
Yumin Luo
Keyword(s):  
Oxidative Stress ◽  
Cerebral Ischemia ◽  
Brain Dysfunction ◽  
Cerebrovascular Diseases ◽  
Pathophysiological Mechanism ◽  
Chronic Cerebral Ischemia ◽  
Celery Seed ◽  
Prevention And Treatment ◽  
Ischemic Cerebrovascular Diseases ◽  
The Common

: Chronic cerebral ischemia is one of the common ischemic cerebrovascular diseases. Chronic cerebral ischemia can lead to brain dysfunction, and its pathophysiological mechanism involves inflammation, blood-brain barrier destruction, oxidative stress, and other factors. Due to it being difficult to detect, it is easily overlooked, and it is often only observed following onset of cognitive dysfunction. At present, there are few drugs for this treatment. DL-3-N-BUTYLPHTHALIDE (NBP), a compound extracted from celery seed, may play an important role in protecting against brain damage caused by chronic cerebral ischemia. Therefore, we pay more attention to the prevention and treatment of NBP on chronic cerebral ischemia.

PARAMETERS OF LIGHT-TRANSMISSION AGGREGOMETRY OF PLATELETS AND TECH-POLYMER-TEST IN CHRONIC CEREBRAL ISCHEMIA WITH TRANSIENT ISCHEMIC ATTACKS

2018 ◽  
Author(s):  
Ю.И. Степанова ◽  
Н.И. Нечипуренко ◽  
Л.И. Алехнович
Keyword(s):  
Cerebral Ischemia ◽  
Light Transmission ◽  
Cerebrovascular Diseases ◽  
Control Group ◽  
Chronic Cerebral Ischemia ◽  
Acute Cerebral Ischemia ◽  
Light Transmission Aggregometry ◽  
Ischemic Cerebrovascular Diseases ◽  
Ischemic Attack ◽  
Diagnostics And Therapy

Цель исследования: провести сравнительный анализ состояния системы гемостаза у пациентов с транзиторной ишемической атакой (ТИА) на фоне хронической ишемии мозга (ХИМ) для оптимизации диагностики и терапии острых ишемических цереброваскулярных заболеваний. Материалы и методы. Обследовано 19 пациентов с ТИА (длительностью не более 24 часов) и 44 пациента с ХИМ в первые и на 8 ± 2 сутки госпитализации. Контрольную группу составили 55 практически здоровых добровольцев. Определяли параметры оптической агрегатометрии тромбоцитов (ОАТ) и Тех-Полимер-теста (ТПТ). Результаты. Продемонстрированы статистически значимые различия состояния первичного и вторичного гемостаза у пациентов с ТИА в сравнении с данными здоровых добровольцев и лиц с ХИМ без ТИА. Заключение. Проведение ОАТ и ТПТ в динамике острой ишемии мозга позволяет получить дополнительный диагностический инструмент для дифференциации пациентов с ТИА на фоне ХИМ и оценить эффективность антитромботической терапии. Aim: to perform a comparative analysis of hemostasis in patients with transient ischemic attack (TIA) in chronic cerebral ischemia (CCI) for optimization of diagnostics and therapy of acute ischemic cerebrovascular diseases. Materials and methods. We examined 19 patients with TIA (not above 24 hours) and 44 patients with CCI at the fi rst day and on 8 ± 2 days of hospitalization. The control group consisted of 55 practically healthy volunteers. The parameters of lighttransmission aggregometry (LTA) of platelets and Tech-Polymer-test (TPT) were determined. Results. Statistically signifi cant diff erences in primary and secondary hemostasis in patients with TIA and CCI were shown in comparison with parameters of healthy persons and patients with CCI without TIA. Conclusion. Using of LTA and TPT in dynamics of acute cerebral ischemia allows to obtain an additional diagnostic instrument for differentiating patients with TIA and CCI and to evaluate the effectiveness of antithrombotic therapy.

Correction of oxidative stress in patients with chronic cerebral ischemia

2016 ◽  
Vol 94 (7) ◽  
pp. 549-553
Author(s):  
Olga A. Goroshko ◽  
K. N. Novikov ◽  
V. G. Kukes ◽  
V. L. Voeikov ◽  
V. V. Arkhipov ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Superoxide Dismutase ◽  
Cerebral Ischemia ◽  
Pilot Study ◽  
Superoxide Anion ◽  
Anion Radical ◽  
Feedback Mechanism ◽  
Chronic Cerebral Ischemia ◽  
Peroxidation Product ◽  
Reasonable Use

A pilot study ofthe effect ofthe antioxidant drug ethylmethylhydroxypyridine malate on indicators of oxidative stress in patients with chronic cerebral ischemia. At 6 day course administration investigated the antioxidant in these patients significantly accelerates the process of generation of superoxide anion radical, established by lucigenin-depended chemiluminescence that probably regulate a feedback mechanism oxidase systems. This increases the activity of superoxide dismutase, and reduced the concentration of secondary peroxidation product - malondialdehyde, making reasonable use of antioxidants in the treatment of this pathology.

Immunopathogenesis and immunotherapeutic approaches of neurodegenerative and cerebrovascular diseases with cognitive impairment. The current state of the problem and prospects

2021 ◽  
Vol 26 (5) ◽  
pp. 4-15
Author(s):  
A. A. Smirnova ◽  
L. N. Prakhova ◽  
A. G. Ilves
Keyword(s):  
Cerebral Ischemia ◽  
Cognitive Decline ◽  
Cerebrovascular Disorders ◽  
Modern Society ◽  
Cerebrovascular Diseases ◽  
Medical Laboratory ◽  
Chronic Cerebral Ischemia ◽  
Age Related ◽  
Limited Effectiveness ◽  
Molecular Patterns

Cognitive impairments (CI) are a serious problem in modern society, because they significantly reduce patients’ quality of life and tend to progress. Age-related diseases such as neurodegenerative — first of all Alzheimer’s disease (AD) and cerebrovascular disorders are key causes leading to CI. At present, approaches to treating these diseases have limited effectiveness in restoring cognitive functions, and do not change disease course, although they can slow cognitive decline.Understanding the immunopathogenesis of neurodegenerative and cerebrovascular diseases defines new targets and approaches to their treatment. In addition, suppression of neuroinflammation is advisable in the cases of early nonclarified cognitive decline, when information from routine medical, laboratory and instrumental examination of patients is insufficient to identify the causes of CI.This article summarizes current understanding of the immunopathogenesis of AD and chronic cerebral ischemia. The mechanism of neuroinflammation is presented as a cascade of sequential events that are closed in a self-perpetuating inflammatory response in the end. So called damage-associated molecular patterns, specific receptors that can bind them (pattern recognition receptors), intracellular signal transduction in microglia, cytokines and adhesion molecules are considered as potential points of application of immunomodulatory therapy. The review provides information on the current level of development of immunotherapy of AD, chronic cerebral ischemia and offers the prospect of its application.

scholarly journals Disorders of the immune status in patients with chronic cerebral ischemia; differentiated pharmacological correction

2018 ◽  
Vol 4 (2) ◽  
pp. 105-123
Author(s):  
Anastasiya Shulginova ◽  
Alexander Konoplya ◽  
Natalya Bystrova
Keyword(s):  
Cerebral Ischemia ◽  
Arterial Hypertension ◽  
Cerebrovascular Diseases ◽  
Pharmacological Therapy ◽  
Control Group ◽  
Etiologic Factor ◽  
Immune Disorders ◽  
Chronic Cerebral Ischemia ◽  
Immune Disorder ◽  
Pharmacological Correction

Introduction: Chronic cerebral ischemia (CCI) accounts for 60-75% of all cerebrovascular diseases in Russia and around the world. The problem: the issues concerning the role of immunity in the pathogenesis of CCI depending on the main etiologic factor and stage of the disease are hardly elaborated, which makes the main pharmacological correction impossible. The objective of the study is to establish the immune disorder patterns in patients with CCI I-II associated with arterial hypertension and to develop differentiated pharmacological methods for their correction. Material and methods: The results of treatment of 104 patients of Kursk Regional Clinical Hospital with CCI associated with II-stage arterial hypertension were analyzed: 52 patients were with CCI I stage (2th-4th groups of 12-14 patients) and 52 patients were with CCI II stage (5th -7th groups of 12-14 patients), aged 50±5, who received the basic pharmacological therapy (enalapril and vinpocetine). The patients of the 2nd and 5th groups additionally received ceraxon and mexicor, those of the 3rd and the 6th groups additionally received immunomodulator glutoxim, and those from the 4th and 7th groups received polyoxidonium. Twenty-two healthy donors were in the control group. Immune disorders were assessed by the parameters of the functional activity of neutrophils, levels of cytokines in plasma, components of the complement and inhibitors. Results and discussion: In the case of CCI I and II stages similar proinflamatory immune disorders were detected, which is indicative of immune inflammation. The inclusion of glutoxime and polyoxidonium in a complex pharmacotherapy helps reduce the severity of immune and neuropsychic status indicators, which are more evident in case of stage II. Conclusions: In case of CCI I stage, the medications used can be arranged according to their clinico-immunological efficacy in ascending order: ceraxon+mexicore ® ceraxon+mexicor+glutoxim ® ceraxon+mexicor+polyoxidonium, and in case of CCI II stage: ceraxon+mexicor ® ceraxon+mexicor+polyoxidonium = ceraxon+mexicor+glutoxim.

Interaction of Oxidative Stress and the Clinical Course of Chronic Cerebral Ischemia

2014 ◽  
Vol 45 (1) ◽  
pp. 36-41
Author(s):  
O. A. Azizova ◽  
E. Yu. Solov’eva ◽  
A. V. Aseichev ◽  
O. A. Baranova ◽  
E. M. Bekman ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Cerebral Ischemia ◽  
Clinical Course ◽  
Chronic Cerebral Ischemia

scholarly journals Role of microRNAs in Stroke and Poststroke Depression

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Han Yan ◽  
Min Fang ◽  
Xue-Yuan Liu
Keyword(s):  
Cerebral Ischemia ◽  
Noncoding Rnas ◽  
Cerebrovascular Diseases ◽  
Eukaryotic Cells ◽  
Poststroke Depression ◽  
Regulate Gene Expression ◽  
Diagnosis And Prognosis ◽  
Ischemic Cerebrovascular Diseases ◽  
Growth Development

microRNAs (miRNA), a sort of noncoding RNAs widely distributed in eukaryotic cells, could regulate gene expression by inhibiting transcription or translation. They were involved in important physiological and pathological processes including growth, development, and occurrence and progression of diseases. miRNAs are crucial for the development of the nervous system. Recent studies have demonstrated that some miRNAs play important roles in the occurrence and development of ischemic cerebrovascular diseases such as stroke and were also involved in the occurrence and development of poststroke depression (PSD). Herein, studies on the role of miRNAs in the cerebral ischemia and PSD were reviewed, and results may be helpful for the diagnosis and prognosis of cerebral ischemia and PSD with miRNAs in clinical practice.

scholarly journals Chronic cerebrovascular diseases: use of vinpocetine in neurological practice (Round Table proceedings)

2018 ◽  
Vol 10 (4) ◽  
pp. 139-145 ◽  
Author(s):  
V. A. Parfenov ◽  
S. A. Zhivolupov ◽  
V. V. Zakharov ◽  
L. A. Belova ◽  
O. V. Lagoda ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Cognitive Impairment ◽  
Cerebral Ischemia ◽  
Neurological Diseases ◽  
Round Table ◽  
Vascular Cognitive Impairment ◽  
Cerebrovascular Diseases ◽  
Chronic Cerebral Ischemia ◽  
Dyscirculatory Encephalopathy ◽  
Clinical Presentations

The paper presents the proceedings of the Round Table with the participation of leading neurologists, which is devoted to chronic cerebrovascular diseases. It is noted that chronic cerebral ischemia (CCI), or dyscirculatory encephalopathy (DEP), is one of the most common neurological diagnoses in our country. The pathogenesis, clinical presentations, diagnosis and treatment of CCI (DEP) and its matching with vascular cognitive impairment (CI), which is regarded in foreign literature as the main manifestation of chronic cerebrovascular disease (CVD) were considered. The authors analyze clinical trials evaluating the efficacy of vinpocetine (Cavinton) in chronic CVD, dizziness, CI, as well as the use of new vinpocetine formulations, such as Cavinton Comforte, in various neurological diseases, dysphagia in particular, in poststroke patients.

Exploring the Chemistry and Therapeutic Potential of Triazoles: A Comprehensive Literature Review

2019 ◽  
Vol 19 (16) ◽  
pp. 1298-1368 ◽  
Author(s):  
Ankit Jain ◽  
Poonam Piplani
Keyword(s):  
Oxidative Stress ◽  
Drug Discovery ◽  
Literature Review ◽  
Structural Modification ◽  
Therapeutic Potential ◽  
Pharmacological Properties ◽  
Pharmacological Activities ◽  
Triazole Derivatives ◽  
Comprehensive Literature Review ◽  
The Common

: Triazole is a valuable platform in medicinal chemistry, possessing assorted pharmacological properties, which could play a major role in the common mechanisms associated with various disorders like cancer, infections, inflammation, convulsions, oxidative stress and neurodegeneration. Structural modification of this scaffold could be helpful in the generation of new therapeutically useful agents. Although research endeavors are moving towards the growth of synthetic analogs of triazole, there is still a lot of scope to achieve drug discovery break-through in this area. Upcoming therapeutic prospective of this moiety has captured the attention of medicinal chemists to synthesize novel triazole derivatives. The authors amalgamated the chemistry, synthetic strategies and detailed pharmacological activities of the triazole nucleus in the present review. Information regarding the marketed triazole derivatives has also been incorporated. The objective of the review is to provide insights to designing and synthesizing novel triazole derivatives with advanced and unexplored pharmacological implications.

Citimax-Darnitsa in the treatment of patients with chronic cerebral ischemia

2017 ◽  
Vol 0 (1.87) ◽  
pp. 117-122
Author(s):  
O.L. Tovazhnianska ◽  
I.O. Lapshina ◽  
A.H. Chernenko ◽  
O.I. Kauk
Keyword(s):  
Cerebral Ischemia ◽  
Chronic Cerebral Ischemia
Sign in / Sign up

Export Citation Format

Share Document